CRS members receive a free online subscription
Drug Delivery and Translational Research is a journal published by CRS, providing a unique forum for scientific publication of high-quality research that is exclusively focused on translational aspects of drug delivery. The journal is published 6 times a year and will be available online to CRS members as part of their annual dues.
We welcome research focused on the following areas of translational drug delivery research:
- Designing and developing novel drug delivery systems, with a focus on their application to disease conditions
- Preclinical and clinical data related to drug delivery systems
- Drug distribution, pharmacokinetics, clearance, with drug delivery systems as compared to traditional dosing to demonstrate beneficial outcomes
- Short-term and long-term biocompatibility of drug delivery systems, host response
- Biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering
- Image-guided drug therapy
- Devices for drug delivery and drug/device combination products
In addition to original full-length papers, communications, and reviews, the journal will also include editorials, reports of future meetings, research highlights, and announcements pertaining to the activities of CRS.
This newly published DDTR “Perspective” article discusses the roles of drug delivery technologies in developing safe and efficacious vaccines. We thank Drs. Robert Langer, Pieter Cullis, Olivia Merkel and Mark Prausnitz for sharing their perspectives and insights on this important topic.
Best Paper of the June 2022 Issue of DDTR:
Summary: The goal of the current research was to develop an ImM (tyrosine kinase inhibitor) containing nanoformulation and to determine if kidney delivery could be improved over traditional ImM in order to potentially treat nephritis secondary to systemic lupus erythematosus (SLEN). The glomerulus is the location within the kidney targeted in SLEN. A fish oil–based ImM oil-in-water nanoemulsion was developed and characterized for particle size, zeta potential, pH, and stability. MRL/MpJ-Faslpr (a mouse model of SLEN) and control mice (MRL-MpJ) were employed. The nanoemulsion characteristics were favorable for renal deposition (60-80 nm size, zeta potential of −6.6 to −7.8 mV, polydispersity index < 0.3, 3-day stability at 4 °C) and demonstrated limited leakage. Kidney deposition of ImM was found to be threefold higher in mice that received the nanoformulation versus naked formulation. Future strategies will define dose-efficacy and dose-toxicity relationships, and characterize and evaluate approaches to further enhance kidney deposition.
Melanie Joy talks about DDTR, an official journal of the CRS.
Editor-in-Chief María José Alonso, PhD talks about DDTR, an official journal of the CRS.
Prof. Ben Boyd, President of the CRS and Editor of DDTR, talks about his experience with the DDTR, an official journal of the CRS.
In this inspirational note, James Goodson and Dr. Paul Rota provide insightful and timely perspective and discussion regarding the importance of vaccine delivery technology and multidisciplinary efforts to achieve global vaccination and ultimately well-being.
In this Inspirational Note, Dr. Andrew Lewis and coauthors feature an amazing and innovative discovery that is changing the paradigm of oral peptide delivery.
2020 DDTR Best Paper of the Year: Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type B.
2019 DDTR Best Paper of the Year: Depletion of collagen by losartan to improve tumor accumulation and therapeutic efficacy of photodynamic nanoplatforms
2019 CRS Nanomedicine and Nanoscale Delivery (NND) Best Paper of the Year: Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8+ T cell immune responses
2019 DDTR CRS Oral Drug Delivery Focus Group Paper of the Year Award: Loratadine self-microemulsifying drug delivery systems (SMEDDS) in combination with sulforaphane for the synergistic chemoprevention of pancreatic cancer
Read DDTR's First Inspirational Note: Contraceptive technologies for global health: ethically getting to safe, effective and acceptable options for women and men
Maria José Alonso, PhD - University of Santiago de Complotela, Spain